与血清前列腺特异性抗原（PSA）和前列腺酸性磷酸酶（PAP）相比，尿转铁蛋白在前列腺癌患者中的诊断价值。

The diagnostic value of urinary transferrin compared to serum prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) in patients with prostatic cancer.

作者信息

van Dieijen-Visser M P, Hendriks M W, Delaere K P, Gijzen A H, Brombacher P J

机构信息

Department of Clinical Chemistry, De Wever-Hospital, Heerlen, The Netherlands.

出版信息

Clin Chim Acta. 1988 Sep 30;177(1):77-80. doi: 10.1016/0009-8981(88)90309-9.

DOI:10.1016/0009-8981(88)90309-9

PMID:2460272

Abstract

Urinary transferrin, serum prostatic acid phosphatase (PAP) and prostatic-specific antigen (PSA) concentrations were measured in patients with prostatic cancer, prostatitis, benign prostatic hypertrophy (BPH) and in a control group. In contrast to recently published data it is concluded that urinary transferrin is not suitable as a tumor marker for prostatic carcinoma. Receiver Operating Characteristic curves were constructed to compare the diagnostic value of the different tests at different cutoff values. Sensitivity and specificity of the urinary marker are extremely low compared to the serum markers PAP and especially PSA, making the former not suitable as an additional marker.

摘要

对前列腺癌、前列腺炎、良性前列腺增生（BPH）患者及对照组测定了尿转铁蛋白、血清前列腺酸性磷酸酶（PAP）和前列腺特异性抗原（PSA）浓度。与最近发表的数据相反，得出的结论是尿转铁蛋白不适合作为前列腺癌的肿瘤标志物。构建了受试者工作特征曲线，以比较不同检测在不同临界值下的诊断价值。与血清标志物PAP尤其是PSA相比，尿标志物的敏感性和特异性极低，这使得前者不适合作为辅助标志物。